Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848561 · ClinicalTrials.gov registry record
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
A clinical trial of Ulcerative Colitis (UC), sponsored by AbbVie.
- Active
- Registry status
- 8,250
- Enrollment target
- 20
- Study locations
NCT01848561: Active study of Ulcerative Colitis (UC), sponsored by AbbVie.
NCT01848561 is a study of Ulcerative Colitis (UC) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 8,250 participants, above the 280-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (2846% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01848561, a study of Ulcerative Colitis (UC), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- 8,250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
Conditions Studied
Study Locations (20)
California
- Southern California Res. Ctr. /ID# 116898 - Coronado
- Moores Cancer Center at UC San Diego /ID# 133722 - La Jolla
- McGuire, Jr. La Mirada, CA /ID# 116257 - La Mirada
- Atay, Los Alamitos, CA /ID# 110175 - Los Alamitos
- Temecula Valley Endoscopy Ctr /ID# 118660 - Murrieta
- Community Clinical Trials, CA /ID# 117335 - Orange
- Digestive Care Medical Center /ID# 122075 - San Carlos
- Precision Research Institute - San Diego /ID# 103638 - San Diego
- Precision Research Institute - San Diego /ID# 113445 - San Diego
- Santa Monica Research Institut /ID# 118675 - Santa Monica
- Duplicate_St. Joseph Heritage Group - Yorba Linda /ID# 133721 - Yorba Linda
Alabama
- Birmingham Gastroenterology Associates P.C /ID# 102063 - Birmingham
- University of Alabama at Birmingham - Main /ID# 131646 - Birmingham
- Longwood Research /ID# 118662 - Huntsville
- East View Medical Research, LLC /ID# 116259 - Mobile
- Mobile Medical & Diagnostic Center, AL /ID# 102064 - Mobile
Arizona
- HOPE Research Institute /ID# 127947 - Phoenix
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 140387 - Tucson
- University Of Arizona /ID# 117836 - Tucson
Arkansas
- Arkansas Gastroenterology /ID# 113898 - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,250 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2028-06 |
What the registry record for NCT01848561 still lists
NCT01848561 is an observational study that tracks outcomes without assigning an intervention. Its 8,250 participants enrollment target places it among the larger protocols in the corpus, above the 280-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (2846% higher).
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 0 interventions.
NCT01848561 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01848561 about?
NCT01848561 is a clinical study titled "A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)". This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
What is the current status of trial NCT01848561?
This trial is currently active not recruiting. The enrollment target is 8,250 participants. The study started on 2013-04-29. Estimated completion is 2028-06.
What conditions does trial NCT01848561 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
Who is sponsoring clinical trial NCT01848561?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01848561 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01848561's enrollment target sits among peer trials
8,250 1st of 17 higher than 17 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
- NCT06435806 · 8,200 participants · NA
Medical Illustration Design Characteristic Evaluation
- NCT06184945 · 8,100 participants · NA
Behavioral Economic & Staffing Strategies in the ICU
- NCT05593484 · 8,060 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI